| Literature DB >> 20671959 |
Bianca Knoch1, Matthew P G Barnett, Janine Cooney, Warren C McNabb, Diane Barraclough, William Laing, Shuotun Zhu, Zaneta A Park, Paul Maclean, Scott O Knowles, Nicole C Roy.
Abstract
The interleukin-10 gene-deficient (Il10(-/-)) mouse is a model of human inflammatory bowel disease and Ppara has been identified as one of the key genes involved in regulation of colitis in the bacterially inoculated Il10(-/-) model. The aims were to (1) characterize colitis onset and progression using a histopathological, transcriptomic, and proteomic approach and (2) investigate links between PPARalpha and IL10 using gene network analysis. Bacterial inoculation resulted in severe colitis in Il10(-/-) mice from 10 to 12 weeks of age. Innate and adaptive immune responses showed differences in gene expression relating to colitis severity. Actin cytoskeleton dynamics, innate immunity, and apoptosis-linked gene and protein expression data suggested a delayed remodeling process in 12-week-old Il10(-/-) mice. Gene expression changes in 12-week-old Il10(-/-) mice were related to PPARalpha signaling likely to control colitis, but how PPARalpha activation might regulate intestinal IL10 production remains to be determined.Entities:
Year: 2010 PMID: 20671959 PMCID: PMC2910480 DOI: 10.1155/2010/621069
Source DB: PubMed Journal: PPAR Res Impact factor: 4.964
Body weight and dietary intake of Il10 −/− and C57 mice at 7, 8.5, 10, 12, and 14 weeks of age.
| Weeks of age | Body weight (g) | Dietary intake (g) | ||
|---|---|---|---|---|
| C57 mice |
| C57 mice |
| |
| 7 | 18.8 ± 0.4 | 18.2 ± 0.8 | 3.4 ± 0.1 | 3.3 ± 0.2 |
| 8.5 | 20.3 ± 0.9 | 19.0 ± 0.3 | 3.6 ± 0.1 | 3.9 ± 0.3 |
| 10 | 22.5 ± 0.6 | 19.9 ± 0.4* | 3.7 ± 0.0 | 3.9 ± 0.1 |
| 12 | 24.8 ± 0.7 | 21.0 ± 0.8* | 3.6 ± 0.1 | 3.5 ± 0.2 |
| 14 | 25.3 ± 0.4 | 19.8 ± 0.7* | 3.6 ± 0.1 | 3.5 ± 0.3 |
Data shown as mean ± standard error of mean (SEM) per group of mice sacrificed. Body weight was measured thrice weekly and dietary intake was estimated and adjusted daily to equal the mean amount of food consumed by Il10 −/− mice on the previous day to ensure similar intakes between C57 and Il10 −/− mice. *P < 0.05 comparing Il10 −/− versus C57 mice of the same age.
Figure 1Total histological injury score for duodenum, jejunum, ileum, and colon sections of Il10 −/− and C57 mice at 7, 8.5, 10, 12, and 14 weeks of age. The individual scores and the average score (—) of each sampling group are shown. Statistical analysis was performed only for total colon HIS of Il10 −/− mice and different letters mean that total colon HIS differs compared to 7-week-old Il10 −/− mice (a, b, P < 0.05 and c, 0.05 < P < 0.1).
Time of onset and incidence of colon inflammation in Il10 −/− mice.
| Weeks of age | 7 | 8.5 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| Number of mice sampled | |||||
|
| 5 | 6 | 6 | 6 | 5 |
| C57 mice (total 30) | 6 | 6 | 6 | 6 | 6 |
| Number of mice with inflamed colon2 | |||||
|
| 2 | 4 | 6 | 6 | 4 |
| C57 mice | 0 | 0 | 0 | 0 | 0 |
| Incidence of colon inflammation (%) | |||||
|
| 40 | 67 | 100 | 100 | 80 |
| C57 mice | 0 | 0 | 0 | 0 | 0 |
1Two Il10 −/− mice died during the study due to unknown causes. 2Mice were regarded as inflamed when their total colon histological injury score (HIS) was >3 (4–6 moderate inflammation, ≥7 severe inflammation). All C57 mice had a total colon HIS ≤ 3.
Figure 2Hematoxylin-eosin-stained colon sections of Il10 −/− and C57 mice. (a) Colon section (×20) from a non-inflamed C57 mouse at 12 weeks of age. (b) Colon section (×100) from an Il10 −/− mouse at 7 weeks of age with no inflammation. (c) Moderate to severe inflamed colon section (×40) from an Il10 −/− mouse at 12 weeks of age. Lesions involve most of the colon section with mainly monocyte and neutrophil infiltration (←), crypt abscesses, and loss of crypt and goblet cells (◂).
Figure 3Genes over-represented in EASE analysis comparing Il10 −/− and C57 mice at 7 or 12 weeks of age. Heat map represents the expression levels of all differentially expressed genes in the significant GO categories (EASE score <0.05 and q < 0.05). The groups are clearly defined within their clusters and differences in gene expression are seen for 12-week-old Il10 −/− mice relative to 7-week-old Il10 −/− mice and 12-week-old C57 mice.
Validation of gene expression results from microarray analysis using qRT-PCR.
| Gene symbol | Fold change microarray | Fold change qRT-PCR | ||
|---|---|---|---|---|
|
|
|
|
| |
|
| −3.4 | −2.8 | −5.2 | −4.9 |
|
| −1.5* | −3.0 | −1.5# | −3.4 |
|
| −1.8* | −3.1 | −2.9 | −5.6 |
|
| −1.9 | −5.6 | −1.5# | −9.8 |
|
| −1.5* | 1.6* | −1.9# | 2.8 |
|
| 1.8* | 6.4 | 3.4 | 8.5 |
|
| 1.0* | 1.8 | 2.7# | 9.9 |
|
| −2.0 | −1.7 | −5.6 | −3.8 |
|
| 1.0* | 1.0* | 1.2# | 1.8 |
|
| −3.2 | −3.1 | −3.6 | −3.3 |
Canx (calnexin) reference gene used to to normalize the data; *microarray result was not significantly different using moderated t-statistics and false discovery rate (FDR) control in limma; genes that satisfied the criterion of FC ≥ 1.5 and q < 0.05 were considered to be significantly different; #qRT-PCR result was not significantly different using ANOVA.
Figure 42D-DIGE gel representing differentially expressed proteins identified in the colon tissue of Il10 −/− mice compared to C57 mice at 7 and 12 weeks of age, respectively. Protein annotations are shown in Table 4. The approximate isoelectric point (pI) and molecular weight (MW) in kDa are given on the x- and y-axes, respectively.
Proteins differentially expressed in the colon of Il10 −/− mice compared to C57 mice at 7 and 12 weeks of age.
| Spot | Accession number | Protein description | Gene (MGI) | Theoretical Mr (kDa) | Theoretical pI | No. peptides matched | Sequence coverage % | SEQUEST P (pro) | Fold change |
|---|---|---|---|---|---|---|---|---|---|
| 7 weeks | |||||||||
| 1 | gi | CAP, adenylate cyclase-associated protein 1 |
| 51.5 | 7.29 | 2 | 4.2 | 9.50E-05 | −2.9 |
| 2 | gi | glutamate dehydrogenase 1 |
| 61.3 | 7.96 | 3 | 6.1 | 2.85E-10 | −2.9 |
| 3 | gi | peroxiredoxin 6 |
| 24.8 | 5.96 | 5 | 27.2 | 3.99E-08 | 3.4 |
|
| |||||||||
| 12 weeks | |||||||||
| 4 | gi | actin, gamma, cytoplasmic 1 |
| 41.8 | 5.20 | 10 | 38.9 | 7.54E-12 | −3.2 |
| 5 | gi | actin, alpha 2, smooth muscle, aorta |
| 42.0 | 5.12 | 3 | 13.3 | 2.13E-06 | −3.2 |
| 6 | gi | actin, gamma, cytoplasmic 1 |
| 41.8 | 5.20 | 9 | 30.7 | 2.76E-10 | −7.4 |
| 7 | gi | actin, gamma 2, smooth muscle, enteric |
| 41.9 | 5.20 | 4 | 20.7 | 1.50E-06 | −7.4 |
| 8 | gi | actin, gamma, cytoplasmic 1 |
| 41.8 | 5.20 | 6 | 15.7 | 7.93E-07 | −2.9 |
| 9 | gi | aldehyde dehydrogenase 1 family, member B1 |
| 57.5 | 6.61 | 8 | 16.6 | 2.88E-09 | −3.3 |
| 10 | gi | apolipoprotein A-I |
| 30.6 | 5.57 | 4 | 16.7 | 5.56E-12 | 2.4 |
| 11 | gi | Rho, GDP dissociation inhibitor (GDI) beta |
| 22.8 | 4.80 | 4 | 22.5 | 4.11E-13 | 2.9 |
| 12 | gi | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 |
| 59.7 | 9.53 | 15 | 35.1 | 3.40E-12 | −2.0 |
| 13 | gi | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 |
| 59.7 | 9.53 | 12 | 27.8 | 1.72E-12 | −2.1 |
| 14 | gi | ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit |
| 56.3 | 5.07 | 16 | 41.8 | 5.47E-12 | −2.1 |
| 15 | gi | calmodulin 1 |
| 16.8 | 3.93 | 3 | 32.9 | 6.21E-11 | 5.0 |
| 16 | gi | carbonic anhydrase 1 |
| 28.3 | 6.49 | 7 | 36.4 | 4.32E-10 | 2.3 |
| 17 | gi | chaperonin subunit 2 (beta) |
| 57.4 | 5.96 | 11 | 26.7 | 2.76E-09 | −2.2 |
| 18 | gi | cofilin 1, non-muscle |
| 18.5 | 8.20 | 4 | 18.8 | 8.89E-09 | 2.9 |
| 19 | gi | cofilin 1, non-muscle |
| 18.5 | 8.20 | 4 | 18.8 | 1.28E-09 | 2.5 |
| 20 | gi | evolutionarily conserved signalling intermediate in Toll pathway |
| 49.7 | 6.14 | 2 | 4.1 | 1.54E-05 | −2.3 |
| 21 | gi | eukaryotic translation elongation factor 2 |
| 95.3 | 6.30 | 10 | 13.4 | 8.98E-12 | −5.8 |
| 22 | gi | EF hand domain containing 2 |
| 26.8 | 4.92 | 5 | 24.2 | 3.42E-08 | 2.0 |
| 23 | gi | eukaryotic translation initiation factor 5A |
| 16.8 | 4.94 | 3 | 20.8 | 9.81E-12 | 2.2 |
| 24 | gi | fatty acid binding protein 4, adipocyte |
| 14.6 | 8.74 | 5 | 48.5 | 1.28E-08 | 2.9 |
| 25 | gi | glutamate dehydrogenase 1 |
| 61.3 | 7.96 | 10 | 20.1 | 7.64E-11 | −2.9 |
| 26 | gi | gelsolin |
| 85.9 | 5.78 | 5 | 10.4 | 5.61E-07 | −2.3 |
| 27 | gi | gelsolin |
| 85.9 | 5.78 | 3 | 4.4 | 2.19E-07 | −2.5 |
| 28 | gi | histidine triad nucleotide binding protein |
| 13.8 | 6.41 | 2 | 16.7 | 1.39E-10 | 2.1 |
| 29 | gi | Cr1 protein |
| 26.3 | 7.97 | 2 | 11.3 | 2.05E-09 | 2.2 |
| 30 | gi | keratin complex 2, basic, gene 8 |
| 54.5 | 5.59 | 16 | 39.6 | 1.20E-11 | −2.0 |
| 31 | gi | keratin complex 1, acidic, gene 19 |
| 44.5 | 5.15 | 6 | 12.9 | 6.39E-10 | −3.2 |
| 32 | gi | keratin complex 1, acidic, gene 19 |
| 44.5 | 5.15 | 13 | 45.4 | 1.82E-08 | −7.4 |
| 33 | gi | keratin complex 1, acidic, gene 19 |
| 44.5 | 5.15 | 9 | 25.3 | 8.96E-10 | −2.9 |
| 34 | gi | heat shock protein 1, beta |
| 83.2 | 4.82 | 15 | 22.1 | 2.47E-10 | −2.8 |
| 35 | gi | heat shock protein 1, beta |
| 83.2 | 4.82 | 17 | 25.3 | 1.01E-11 | −2.1 |
| 36 | gi | mitochondrial ATP-dependent protease Lon |
| 10.6 | 6.20 | 4 | 4.0 | 5.94E-05 | −3.0 |
| 37 | gi | PREDICTED: similar to non-muscle myosin alkali light chain |
| 13.0 | 4.42 | 3 | 34.5 | 7.28E-06 | 5.1 |
| 38 | gi | profilin 1 |
| 15.0 | 8.43 | 6 | 55.7 | 1.42E-12 | 2.9 |
| 39 | gi | PREDICTED: similar to 40S ribosomal protein S12 |
| 14.5 | 6.94 | 2 | 12.1 | 4.18E-04 | 2.1 |
| 40 | gi | S100 calcium binding protein A4 |
| 11.7 | 5.07 | 2 | 17.8 | 1.43E-04 | 2.4 |
| 41 | gi | S100 calcium binding protein A9 (calgranulin B) |
| 13.0 | 6.76 | 4 | 36.3 | 7.54E-06 | 4.0 |
| 42 | gi | S100 calcium binding protein A11 (calgizzarin) |
| 11.1 | 5.15 | 1 | 16.3 | 1.65E-04 | 5.1 |
| 43 | gi | S100 calcium binding protein A11 (calgizzarin) |
| 11.1 | 5.15 | 1 | 16.3 | 3.53E-05 | 3.2 |
| 44 | gi | stress-induced phosphoprotein 1 |
| 62.5 | 6.39 | 7 | 11.6 | 1.31E-05 | −3.9 |
| 45 | gi | sorting nexin 6 |
| 45.0 | 5.47 | 3 | 7.14 | 2.62E-05 | −2.3 |
| 46 | gi | triosephosphate isomerase 1 |
| 26.7 | 7.07 | 3 | 19.3 | 6.59E-09 | 2.1 |
| 47 | gi | tubulin, alpha 1C |
| 50.1 | 4.83 | 12 | 34.5 | 1.26E-11 | −2.0 |
| 48 | gi | tubulin, beta 5 |
| 49.7 | 4.64 | 9 | 34.7 | 1.30E-11 | −2.2 |
| 49 | gi | thioredoxin |
| 11.7 | 4.64 | 4 | 31.4 | 4.27E-07 | 2.5 |
| 50 | gi | villin 1 |
| 92.7 | 5.66 | 13 | 18.7 | 8.57E-09 | −3.2 |
| 51 | gi | villin 1 |
| 92.7 | 5.66 | 20 | 26.4 | 4.52E-08 | −4.6 |
| 52 | gi | villin 2 |
| 69.4 | 5.76 | 7 | 14.8 | 3.15E-09 | −2.4 |
| 53 | gi | villin 2 |
| 69.4 | 5.76 | 8 | 15.9 | 1.99E-08 | −2.6 |
Categories of genes with expression increase of 2-fold or more in Il10 −/− mice compared to C57 mice at 7 weeks of age using EASE.
| System | Gene category | EASE score | FDR |
|---|---|---|---|
| GO Cellular Component | spindle cell | 3.91E-04 | <0.001 |
| GO Molecular Function | MHC class II receptor activity | 1.25E-03 | <0.001 |
| GO Biological Process | antigen processing, exogenous antigen via MHC class II | 1.37E-03 | <0.001 |
| GO Biological Process | antigen presentation, exogenous antigen | 1.37E-03 | <0.001 |
| GO Biological Process | alcohol metabolism | 2.27E-03 | <0.001 |
| GO Biological Process | glucose metabolism | 4.37E-03 | <0.001 |
| GO Biological Process | main pathways of carbohydrate metabolism | 6.39E-03 | <0.001 |
| GO Biological Process | protein targeting | 7.76E-03 | <0.001 |
| GO Biological Process | steroid biosynthesis | 1.02E-02 | <0.001 |
| GO Biological Process | steroid metabolism | 1.09E-02 | <0.001 |
| GO Biological Process | sterol biosynthesis | 1.29E-02 | <0.001 |
| GO Cellular Component | microtubule cytoskeleton | 1.75E-02 | <0.001 |
| GO Biological Process | sterol metabolism | 1.82E-02 | <0.001 |
| GO Biological Process | carbohydrate metabolism | 1.89E-02 | <0.001 |
| GO Biological Process | hexose metabolism | 1.92E-02 | <0.001 |
| GO Molecular Function | oxidoreductase activity, acting on CH-OH group of donors | 1.96E-02 | <0.001 |
| GO Biological Process | energy derivation by oxidation of organic compounds | 2.47E-02 | <0.001 |
| GO Biological Process | catabolism | 2.54E-02 | <0.001 |
| GO Cellular Component | soluble fraction | 2.82E-02 | <0.001 |
| GO Molecular Function | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 2.92E-02 | <0.001 |
| GO Biological Process | monosaccharide metabolism | 3.13E-02 | <0.001 |
Proteome and transcriptome network analysis for expression profiles from the colon of 7- and 12-week-old Il10 −/− mice compared to C57 mice using IPA.
| Network | Top functional categories |
|---|---|
|
| |
| Transcriptome 1 | Cancer, Dermatological disease and conditions, Endocrine system development and function |
| Transcriptome 2 | Cardiovascular system development and function, Cancer, Tissue development |
| Transcriptome 3 | Cancer, Cell death, Reproductive system disease |
| Transcriptome 4 | Cell cycle, Cell-mediated immune response, Cancer |
| Transcriptome 5 | Cellular growth and proliferation, Hematological system development and function, Hematopoiesis |
|
| |
|
| |
| Proteome 1 | Tissue morphology, Cellular movement, Cell-mediated immune response |
| Proteome 2 | Cell death, Hematological disease, Immunological disease |
| Proteome 3 | Cancer, Tumour morphology, Cellular development |
| Proteome 4 | Cardiovascular disease, Gene expression, Molecular transport |
| Transcriptome 1 | Antigen presentation, Cell morphology, Cell-to-cell signaling and interaction |
| Transcriptome 2 | Cancer, Gastrointestinal disease, Dermatological diseases and conditions |
| Transcriptome 3 | Lipid metabolism, Small molecule biochemistry, Carbohydrate metabolism |
| Transcriptome 4 | Inflammatory disease, Cell-to-cell signaling and interaction, Cell-mediated immune response |
The top 3 biological functions for the most significant transcriptomic and proteomic networks (representing subsets of focus genes and proteins highly associated with those functions) are shown.
Differentially expressed genes in the colon of Il10 −/− mice compared to C57 mice at 7 and 12 weeks of age.
| Gene symbol | Gene name | GenBank accession |
|
| ||
|---|---|---|---|---|---|---|
| 7 weeks of age | 12 weeks of age | |||||
| FC | FDR | FC | FDR | |||
|
| actin, gamma 2, smooth muscle, enteric | NM_007392 | −1.3 | 0.315 | −1.6 | 0.02 |
|
| Rho GTPase activating protein 12 | NM_029277 | −1.1 | 0.549 | −1.5 | <0.001 |
|
| Rho GDP dissociation inhibitor (GDI) beta | NM_007486 | 1.1 | 0.562 | 2.0 | <0.001 |
|
| Rho guanine nucleotide exchange factor (GEF) 10-like | AK028648 | 2.4 | <0.001 | 2.3 | <0.001 |
|
| BCL2-related protein A1 | NM_007534 | 1.6 | 0.001 | 2.7 | <0.001 |
|
| B-cell CLL/lymphoma 3 | NM_033601 | 1.6 | 0.044 | 1.7 | 0.015 |
|
| complement component 1, q subcomponent, A chain | NM_007572 | 1.1 | 0.67 | 1.6 | 0.003 |
|
| complement component 1, q subcomponent, C chain | NM_007574 | 1.3 | 0.29 | 1.8 | 0.005 |
|
| complement component 1, r subcomponent | NM_023143 | 1.5 | 0.018 | 2.0 | <0.001 |
|
| complement component 1, s subcomponent | NM_144938 | 1.3 | 0.059 | 1.9 | <0.001 |
|
| complement component 2 | NM_013484 | 1.2 | 0.337 | 2.6 | <0.001 |
|
| complement component 3 | NM_009778 | 1.8 | 0.015 | 4.5 | <0.001 |
|
| complement component 4B (Chido blood group) | NM_009780 | −1.0 | 0.976 | 1.6 | 0.005 |
|
| chemokine (C-C-motif) ligand 5 (Rantes) | NM_013653 | 1.1 | 0.7 | 2.3 | <0.001 |
|
| CD74 molecule, major histocompatibility complex, class II invariant chain | NM_010545 | 4.0 | <0.001 | 5.5 | <0.001 |
|
| Fas (TNF receptor superfamily, member 6) | NM_007987 | 1.9 | <0.001 | 1.5 | <0.001 |
|
| gelsolin | NM_146120 | −1.8 | 0.006 | −2.0 | <0.001 |
|
| major histocompatibility complex, class I, A | NM_010391 | 1.4 | 0.201 | 2.3 | <0.001 |
|
| major histocompatibility complex, class I, B | NM_008199 | −1.4 | 0.104 | 1.9 | <0.001 |
|
| major histocompatibility complex, class I, C | NM_010380 | 1.4 | 0.005 | 2.3 | <0.001 |
|
| major histocompatibility complex, class II, DM alpha | NM_010386 | 1.5 | <0.001 | 2.1 | <0.001 |
|
| major histocompatibility complex, class II, DM beta | NM_010387 | 4.9 | <0.001 | 6.6 | <0.001 |
|
| major histocompatibility complex, class II, DQ alpha 1 | NM_010378 | 1.8 | <0.001 | 2.9 | <0.001 |
|
| major histocompatibility complex, class II, DQ beta 2 | NM_010379 | 3.1 | <0.001 | 5.3 | <0.001 |
|
| major histocompatibility complex, class II, DR beta 1 | NM_010382 | 2.5 | <0.001 | 4.5 | <0.001 |
|
| major histocompatibility complex, class I, G | NM_013819 | 1.4 | 0.013 | 2.0 | <0.001 |
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A reductase | NM_008255 | 1.7 | 0.005 | 1.5 | 0.005 |
|
| indoleamine 2,3-dioxygenase 1 | NM_008324 | 6.6 | <0.001 | 8.1 | <0.001 |
|
| interferon, gamma | NM_008337 | 1.4 | 0.071 | 1.7 | 0.003 |
|
| interleukin 1, beta | NM_008361 | 1.8 | 0.211 | 6.4 | <0.001 |
|
| interleukin 1 receptor antagonist | NM_031167 | 1.3 | 0.442 | 1.8 | 0.024 |
|
| interleukin 10 | NM_010548 | 1.1 | 0.461 | 1.1 | 0.421 |
|
| mitogen-activated protein kinase 13 | NM_011950 | 1.8 | <0.001 | 1.7 | <0.001 |
|
| mitogen-activated protein kinase 9 | NM_016961 | 1.5 | 0.004 | 1.6 | <0.001 |
|
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | NM_010907 | 1.6 | 0.002 | 1.6 | 0.001 |
|
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon | NM_008690 | 1.5 | 0.001 | 1.7 | <0.001 |
|
| peroxisome proliferator-activated receptor alpha | NM_011144 | −2.0 | <0.001 | −1.7 | 0.001 |
|
| peroxisome proliferator-activated receptor gamma, coactivator 1 alpha | NM_008904 | −1.7 | 0.008 | −1.4 | 0.052 |
|
| toll-like receptor 2 | NM_011905 | 1.1 | 0.857 | 1.9 | 0.001 |
|
| toll-like receptor 9 | NM_031178 | 1.9 | <0.001 | 1.9 | <0.001 |
|
| tumour necrosis factor (TNF superfamily, member 2) | NM_013693 | 1.3 | 0.064 | 1.7 | <0.001 |
|
| tumour necrosis factor receptor superfamily, member 1B | NM_011610 | 1.3 | 0.115 | 1.5 | 0.003 |
|
| thioredoxin | NM_011660 | −1.2 | 0.494 | −1.0 | 0.932 |
Genes were grouped into one or more of the following IPA pathways: antigen presentation, graft versus host disease signaling, allograft rejection signaling, interferon signaling, role of PKR in interferon induction and antiviral response, dendritic cell maturation, complement system, endoplasmic reticulum stress, and steroid metabolism. Genes with fold change (FC) ≥1.5 and false discovery rate (FDR) or q < 0.05 were considered for pathway analysis.
Categories of genes with expression increase of 2-fold or more in Il10 −/−mice compared to C57 mice at 12 weeks of age using EASE.
| System | Gene category | EASE score | FDR |
|---|---|---|---|
| GO Biological Process | defence response | 5.92E-14 | <0.001 |
| GO Biological Process | response to biotic stimulus | 7.39E-14 | <0.001 |
| GO Biological Process | response to external stimulus | 1.38E-12 | <0.001 |
| GO Biological Process | immune response | 4.06E-12 | <0.001 |
| GO Biological Process | antigen presentation | 4.14E-07 | <0.001 |
| GO Biological Process | antigen processing | 4.52E-06 | <0.001 |
| GO Molecular Function | defence/immunity protein activity | 6.14E-06 | <0.001 |
| GO Molecular Function | MHC class I receptor activity | 2.67E-05 | <0.001 |
| GO Biological Process | response to pest/pathogen/parasite | 1.43E-04 | <0.001 |
| GO Biological Process | physiological process | 1.47E-04 | <0.001 |
| GO Molecular Function | antigen binding | 2.31E-04 | <0.001 |
| GO Biological Process | response to stress | 2.49E-04 | <0.001 |
| GO Biological Process | antigen presentation, endogenous antigen | 1.21E-03 | <0.001 |
| GO Molecular Function | MHC class II receptor activity | 1.56E-03 | <0.001 |
| GO Biological Process | antigen processing, exogenous antigen via MHC class II | 1.67E-03 | <0.001 |
| GO Biological Process | antigen presentation, exogenous antigen | 1.67E-03 | <0.001 |
| GO Cellular Component | extracellular space | 1.75E-03 | <0.001 |
| GO Biological Process | protein targeting | 2.57E-03 | <0.001 |
| GO Biological Process | humoral immune response | 2.97E-03 | <0.001 |
| GO Cellular Component | plasma membrane | 7.23E-03 | <0.001 |
| GO Biological Process | antigen processing, endogenous antigen via MHC class I | 8.44E-03 | <0.001 |
| GO Biological Process | response to wounding | 1.07E-02 | <0.001 |
| GO Molecular Function | oxidoreductase activity, acting on CH-OH group of donors | 1.15E-02 | <0.001 |
| GO Molecular Function | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.71E-02 | <0.001 |
| GO Molecular Function | hydrolase activity | 1.86E-02 | <0.001 |
| GO Biological Process | collagen catabolism | 2.07E-02 | <0.001 |
| GO Biological Process | posttranslational membrane targeting | 2.18E-02 | <0.001 |
| GO Biological Process | innate immune response | 2.22E-02 | <0.001 |
| GO Cellular Component | vesicular fraction | 2.51E-02 | <0.001 |
| GO Biological Process | response to chemical substance | 3.06E-02 | <0.001 |
| GO Biological Process | inflammatory response | 3.06E-02 | <0.001 |